Conjugation Experts to Develop Innovation Therapies
Acepodia’s proprietary Antibody-Cell Conjugation (ACC™) technology is the ultimate solution to the unmet needs in both cell therapy and engagers. The ACC technology is founded on the 2022 Nobel Prize-winning bioorthogonal chemistry from Professor Carolyn Bertozzi. Through ACC technology, tumor-targeting antibodies are conjugated to allogeneic immune cells, such as natural killer and gamma delta 2 T cells.
Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C™) platform enables easy integration of multiple types of linker-payloads through a site-specific conjugation process. This method maintains conjugation efficiency and minimizes the impact on antibody binding capacity.
Antibody-Cell Conjugation (ACC™) technology ,a family of Click Chemistry from Nobel Prize laureate- Professor Carolyn Bertozzi’s Lab binds tumor-targeting antibodies to a variety of receptors of immune cells that allows for better recognition, and can significantly enhance the potency of immune cells.
Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C™) platform enables easy integration of multiple types of linker-payloads through a site-specific conjugation process. This method maintains conjugation efficiency and minimizes the impact on antibody binding capacity.